GlassScriptPhysician profile
Sarah C Case
NPI 1922636851
$4,829.21
in general payments reported to CMS, 2019-2025
33 companies · $1,556 in 2025
The $1,556 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $242 · 2023: $1,781 · 2024: $1,251 · 2025: $1,556.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,067.52 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,041.10 | 2023-2025 | |
| Amgen INC. | $592.17 | 2022-2025 | Otezla, Otezla, Repatha |
| Lilly USA, LLC | $387.72 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $278.75 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $172.68 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $147.34 | 2023-2025 | |
| Pfizer INC. | $142.57 | 2023-2025 | |
| Axsome Therapeutics, INC. | $126.58 | 2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $94.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.27 | 2023-2024 | Jardiance |
| Karl Storz Endoscopy-America | $73.83 | 2022 | |
| Impel Pharmaceuticals INC. | $71.23 | 2023 | Trudhesa |
| Phathom Pharmaceuticals, INC. | $67.44 | 2024 | Voquezna |
| Corcept Therapeutics | $46.36 | 2025 | Korlym |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $43.34 | 2024-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.36 | 2025 | Xifaxan |
| Shield Therapeutics INC | $32.54 | 2023-2025 | Accrufer |
| Idorsia Pharmaceuticals US INC | $32.44 | 2023-2024 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $32.10 | 2023 | Rexulti |
| Radius Health, INC. | $29.36 | 2025 | |
| Janssen Pharmaceuticals, INC | $28.60 | 2024 | Spravato |
| Antares Pharma, INC. | $24.40 | 2023 | Nocdurna, Tlando, Xyosted |
| Vanda Pharmaceuticals INC. | $21.78 | 2024 | Fanapt, Hetlioz |
| Hollister Incorporated | $21.04 | 2023 | Vapro Plus Pocket, Infyna Chic |
| Abbott Laboratories | $20.43 | 2025 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $18.08 | 2023 | Recorlev |
| Phadia US INC. | $17.09 | 2025 | Immunocap |
| Janssen Biotech, INC. | $16.29 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.85 | 2024 | Caplyta |
| Astellas Pharma US INC | $15.00 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $14.83 | 2024 | Nexletol |
| Glaxosmithkline, LLC. | $13.51 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.